

RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT  
U.S. Appln. No. 09/622,439

**REMARKS**

Claims 1-8 are before the Examiner for consideration.

Claims 3-6 have been amended to more fully comply with U.S. claim format. No new matter has been added. Accordingly, Applicants respectfully request entry of the Amendments.

**I. Restriction Requirement**

In the Office Action dated January 30, 2001, the Examiner issued a Restriction Requirement requiring an election as between

**Invention I**, claims 1 and 2, drawn to SREB receptor polypeptides,

**Invention II**, claims 3-6, drawn to a polynucleotide encoding an SREB receptor, an expression vector, a recombinant host cell, and a method of producing a peptide recombinantly,

**Invention III**, claim 7, drawn to a method for screening compounds which bind to the SREB receptor, and

**Invention IV**, claim 8, drawn to an antibody against an SREB receptor.

In response to this Requirement, Applicants elect **Invention II**, claims 3-6, drawn to a polynucleotide encoding an SREB receptor, an expression vector, a recombinant host cell, and a method of producing a peptide recombinantly, without traverse.

Also in the Office Action dated January 30, 2001, the Examiner required Applicants to further select between

**Group A**, the Inventions named above as they pertain to SEQ ID NO: 2,

**Group B**, the Inventions named above as they pertain to SEQ ID NO: 4,

**Group C**, the Inventions named above as they pertain to SEQ ID NO: 6,

RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT  
U.S. Appln. No. 09/622,439

**Group D**, the Inventions named above as they pertain to SEQ ID NO: 22, and

**Group E**, the Inventions named above as they pertain to SEQ ID NO: 26.


In response Applicants select **Group B**, the Inventions named above as they pertain to SEQ ID NO: 4, without traverse.

**II. Conclusion**

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such action is hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, he is kindly requested to contact the undersigned at the telephone number listed below.

Applicants hereby petition for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,



Drew Hissong  
Registration No. 44,765

SUGHRUE, MION, ZINN,  
MACPEAK & SEAS, PLLC  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3213  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Date: February 28, 2001

**APPENDIX**

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE CLAIMS:**

**The claims are amended as follows:**

3. An isolated DNA molecule which comprises a polynucleotide [A gene which has a nucleotide sequence] coding for a [the] G protein-coupled receptor protein which has the amino acid sequence of SEQ ID NO: 4 [described in claim 1].
4. A vector which comprises the polynucleotide of [contains the gene described in] claim 3.
5. A host cell transformed or transfected with the [which contains the] vector of [described in] claim 4.
6. A method for producing a [the] G protein-coupled receptor protein which has the amino acid sequence of SEQ ID NO: 4, [described in claim 1 or 2, or a G protein-coupled receptor protein as an equivalent to said protein, which comprises] comprising culturing the host cell of [using the host cell described in] claim 5 under conditions promoting expression of a G protein-coupled receptor protein, and recovering the G protein-coupled receptor protein so expressed.